Stoke Therapeutics
STOK
118 hedge funds and large institutions have $715M invested in Stoke Therapeutics in 2024 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 19 closing their positions.
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
4% more funds holding
Funds holding: 114 → 118 (+4)
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7.05% less ownership
Funds ownership: 117.62% → 110.57% (-7%)
14% less capital invested
Capital invested by funds: $828M → $715M (-$113M)
80% less call options, than puts
Call options by funds: $94K | Put options by funds: $475K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$7.22M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.79M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.32M |
| 5 |
RI
RTW Investments
New York
|
+$6.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$27.4M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$18.7M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$16.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.2M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.91M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPS
126
Susquehanna Portfolio Strategies
Bala Cynwyd,
Pennsylvania
| – | -$587K | -43,424 | Closed |
|
|
JF
127
Jump Financial
Chicago,
Illinois
| – | -$463K | -34,277 | Closed |
|
|
CIC
128
Chase Investment Counsel
Charlottesville,
Virginia
| – | -$280K | -20,738 | Closed |
|
129
Tudor Investment Corp
Stamford,
Connecticut
| – | -$249K | -18,402 | Closed |
|
|
GCM
130
Ghisallo Capital Management
Boston,
Massachusetts
| – | -$203K | -15,000 | Closed |
|
131
Renaissance Technologies
New York
| – | -$151K | -11,200 | Closed |
|
132
Russell Investments Group
London,
United Kingdom
| – | -$20.6K | -1,527 | Closed |
|
133
Pacer Advisors
Malvern,
Pennsylvania
| – | -$6.13K | -454 | Closed |
|
|
AAP
134
Arax Advisory Partners
Denver,
Colorado
| – | -$2.34K | -173 | Closed |
|
135
Lazard Asset Management
New York
| – | -$2.2K | -155 | -73% |
|
|
QL
136
Quarry LP
New York
| – | -$1.59K | -118 | Closed |
|
137
Bessemer Group
Woodbridge,
New Jersey
| – | +$212 | +15 | New |
|
STOK Hedge Fund Activity: Q3 2024 in Review
118 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2024, worth a combined $715M — down 14% from $828M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new STOK positions and 19 closed out — a net gain of 4 holders — while 39 added to existing stakes and 36 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.3M. The largest seller was Skorpios Trust, cutting an estimated $27.4M.
- 118 institutional investors held Stoke Therapeutics (STOK) as of Q3 2024, up from 114 in Q2 2024.
- Funds reported $715M of Stoke Therapeutics stock for Q3 2024, down 14% quarter-over-quarter.
- 23 funds opened new Stoke Therapeutics positions in Q3 2024 and 19 closed out, a net change of +4 holders.
- The largest Stoke Therapeutics buyer in Q3 2024 was Morgan Stanley, an estimated $10.3M added.
- The largest Stoke Therapeutics seller in Q3 2024 was Skorpios Trust, an estimated $27.4M sold.
Based on aggregated 13F filings for Q3 2024.